Theravance Biopharma Statistics
Share Statistics
Theravance Biopharma has 50M
shares outstanding. The number of shares has increased by 1.72%
in one year.
| Shares Outstanding | 50M |
| Shares Change (YoY) | 1.72% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 91.54% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 415 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 3.89M, so 7.91% of the outstanding
shares have been sold short.
| Short Interest | 3.89M |
| Short % of Shares Out | 7.91% |
| Short % of Float | 15.37% |
| Short Ratio (days to cover) | 17.97 |
Valuation Ratios
The PE ratio is -8.15 and the forward
PE ratio is -8.07.
Theravance Biopharma's PEG ratio is
-0.54.
| PE Ratio | -8.15 |
| Forward PE | -8.07 |
| PS Ratio | 7.14 |
| Forward PS | 1.9 |
| PB Ratio | 2.62 |
| P/FCF Ratio | -38.73 |
| PEG Ratio | -0.54 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Theravance Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.02,
with a Debt / Equity ratio of 0.28.
| Current Ratio | 5.02 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | -1.06 |
| Debt / FCF | -4.2 |
| Interest Coverage | -18.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $663,721.65 |
| Profits Per Employee | $-581,628.87 |
| Employee Count | 97 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 11.8M |
| Effective Tax Rate | -26.46% |
Stock Price Statistics
The stock price has increased by 4.57% in the
last 52 weeks. The beta is -0.1, so Theravance Biopharma's
price volatility has been lower than the market average.
| Beta | -0.1 |
| 52-Week Price Change | 4.57% |
| 50-Day Moving Average | 9.22 |
| 200-Day Moving Average | 8.98 |
| Relative Strength Index (RSI) | 51.44 |
| Average Volume (20 Days) | 274,413 |
Income Statement
In the last 12 months, Theravance Biopharma had revenue of 64.38M
and earned -56.42M
in profits. Earnings per share was -1.15.
| Revenue | 64.38M |
| Gross Profit | 58.37M |
| Operating Income | -46.95M |
| Net Income | -56.42M |
| EBITDA | -46.95M |
| EBIT | -47.16M |
| Earnings Per Share (EPS) | -1.15 |
Full Income StatementBalance Sheet
The company has 37.8M in cash and 49.82M in
debt, giving a net cash position of -12.02M.
| Cash & Cash Equivalents | 37.8M |
| Total Debt | 49.82M |
| Net Cash | -12.02M |
| Retained Earnings | -965.52M |
| Total Assets | 343.58M |
| Working Capital | 118.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -11.54M
and capital expenditures -332K, giving a free cash flow of -11.87M.
| Operating Cash Flow | -11.54M |
| Capital Expenditures | -332K |
| Free Cash Flow | -11.87M |
| FCF Per Share | -0.24 |
Full Cash Flow StatementMargins
Gross margin is 90.66%, with operating and profit margins of -72.92% and -87.63%.
| Gross Margin | 90.66% |
| Operating Margin | -72.92% |
| Pretax Margin | -69.3% |
| Profit Margin | -87.63% |
| EBITDA Margin | -72.92% |
| EBIT Margin | -72.92% |
| FCF Margin | -18.43% |
